Page last updated: 2024-10-28

lidocaine and Parkinson Disease, Secondary

lidocaine has been researched along with Parkinson Disease, Secondary in 1 studies

Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mura, A1
Feldon, J1
Mintz, M1

Other Studies

1 other study available for lidocaine and Parkinson Disease, Secondary

ArticleYear
Reevaluation of the striatal role in the expression of turning behavior in the rat model of Parkinson's disease.
    Brain research, 1998, Oct-12, Volume: 808, Issue:1

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Lidocaine; Male; Motor Activity; Organ Spe

1998